Analysts Set Savara Inc (NASDAQ:SVRA) PT at $9.86

Savara Inc (NASDAQ:SVRA) has been assigned an average recommendation of “Moderate Buy” from the seven research firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $9.86.

A number of equities research analysts have commented on the stock. Wells Fargo & Company began coverage on shares of Savara in a research report on Friday, December 20th. They issued an “overweight” rating and a $8.00 target price for the company. JMP Securities restated a “market outperform” rating and set a $9.00 target price on shares of Savara in a research note on Thursday, December 19th. Evercore ISI reiterated an “in-line” rating and issued a $5.00 price target (down previously from $7.00) on shares of Savara in a research note on Wednesday, November 13th. Finally, HC Wainwright reduced their target price on shares of Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th.

Insider Buying and Selling at Savara

In other Savara news, CEO Matthew Pauls sold 54,702 shares of the stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $3.31, for a total value of $181,063.62. Following the sale, the chief executive officer now directly owns 1,536,379 shares of the company’s stock, valued at approximately $5,085,414.49. This represents a 3.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. 5.13% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Vestal Point Capital LP lifted its stake in shares of Savara by 24.7% in the 3rd quarter. Vestal Point Capital LP now owns 8,090,000 shares of the company’s stock worth $34,302,000 after acquiring an additional 1,600,000 shares during the period. Geode Capital Management LLC boosted its stake in shares of Savara by 10.8% during the 3rd quarter. Geode Capital Management LLC now owns 2,726,850 shares of the company’s stock worth $11,564,000 after purchasing an additional 264,825 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Savara by 238.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 911,617 shares of the company’s stock worth $3,865,000 after purchasing an additional 642,259 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Savara by 54.0% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 690,609 shares of the company’s stock worth $2,928,000 after purchasing an additional 242,249 shares during the last quarter. Finally, Barclays PLC boosted its position in shares of Savara by 217.5% in the third quarter. Barclays PLC now owns 231,005 shares of the company’s stock worth $979,000 after acquiring an additional 158,244 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Price Performance

SVRA stock opened at $2.65 on Thursday. The firm has a 50 day moving average price of $2.92 and a 200-day moving average price of $3.53. Savara has a 52-week low of $2.57 and a 52-week high of $5.70. The firm has a market capitalization of $454.79 million, a price-to-earnings ratio of -6.16 and a beta of 0.63. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.